Bicara Therapeutics (BCAX)
Market Price (2/8/2026): $15.33 | Market Cap: $836.5 MilSector: Health Care | Industry: Biotechnology
Bicara Therapeutics (BCAX)
Market Price (2/8/2026): $15.33Market Cap: $836.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% | Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -103% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -141 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% | ||
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.8 | ||
| Key risksBCAX key risks include [1] the pivotal trial outcome for its lead HNSCC candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -103% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -141 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 18.8 |
| Key risksBCAX key risks include [1] the pivotal trial outcome for its lead HNSCC candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Bicara Therapeutics (BCAX) stock has lost about 5% since 10/31/2025 because of the following key factors:
1. Bicara Therapeutics reported a larger-than-expected net loss in its Third Quarter 2025 financial results. The company announced its Q3 2025 earnings on November 10, 2025, with an Earnings Per Share (EPS) of -$0.67, missing the consensus estimate of -$0.55. Additionally, the net loss for the third quarter of 2025 increased significantly to $36.33 million, compared to a net loss of $17.48 million in the third quarter of 2024.
2. An analyst initiated coverage with a "Neutral" rating, citing concerns about competitive positioning. On December 18, 2025, Mizuho initiated coverage of Bicara Therapeutics with a "Neutral" rating and a price target of $18.00. The firm expressed a view that Bicara's lead product, ficerafusp alfa, is "unfavorably positioned in an increasingly competitive" head and neck cancer landscape.
Show more
1. Bicara Therapeutics reported a larger-than-expected net loss in its Third Quarter 2025 financial results. The company announced its Q3 2025 earnings on November 10, 2025, with an Earnings Per Share (EPS) of -$0.67, missing the consensus estimate of -$0.55. Additionally, the net loss for the third quarter of 2025 increased significantly to $36.33 million, compared to a net loss of $17.48 million in the third quarter of 2024.
2. An analyst initiated coverage with a "Neutral" rating, citing concerns about competitive positioning. On December 18, 2025, Mizuho initiated coverage of Bicara Therapeutics with a "Neutral" rating and a price target of $18.00. The firm expressed a view that Bicara's lead product, ficerafusp alfa, is "unfavorably positioned in an increasingly competitive" head and neck cancer landscape.
Show more
Stock Movement Drivers
Fundamental Drivers
The -5.7% change in BCAX stock from 10/31/2025 to 2/8/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.25 | 15.33 | -5.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 55 | 55 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| BCAX | -5.5% | |
| Market (SPY) | 1.3% | 13.9% |
| Sector (XLV) | 9.3% | 20.9% |
Fundamental Drivers
The 38.0% change in BCAX stock from 7/31/2025 to 2/8/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.11 | 15.33 | 38.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 52 | 55 | -5.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| BCAX | 38.3% | |
| Market (SPY) | 9.6% | 16.8% |
| Sector (XLV) | 21.5% | 31.8% |
Fundamental Drivers
The 21.5% change in BCAX stock from 1/31/2025 to 2/8/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2082026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.62 | 15.33 | 21.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 34 | 55 | -37.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/8/2026| Return | Correlation | |
|---|---|---|
| BCAX | 21.7% | |
| Market (SPY) | 15.8% | 32.8% |
| Sector (XLV) | 8.8% | 34.6% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/8/2026| Return | Correlation | |
|---|---|---|
| BCAX | ||
| Market (SPY) | 76.2% | 31.4% |
| Sector (XLV) | 23.8% | 31.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BCAX Return | - | - | - | -26% | -3% | -10% | -35% |
| Peers Return | -24% | -23% | 25% | -12% | -3% | -2% | -39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| BCAX Win Rate | - | - | - | 25% | 67% | 0% | |
| Peers Win Rate | 40% | 47% | 48% | 47% | 45% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BCAX Max Drawdown | - | - | - | -30% | -50% | -10% | |
| Peers Max Drawdown | -36% | -49% | -23% | -27% | -48% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MGNX, ZYME, IOVA, REGN, MRK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
BCAX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to MGNX, ZYME, IOVA, REGN, MRK
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bicara Therapeutics (BCAX)
We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-ß. Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-ß signaling within the tumor microenvironment, or TME. Ficerafusp alfa directs the TGF-ß inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will lead to durable responses and an increase in overall survival, or OS, while reducing the adverse effects typically associated with systemic TGF-ß inhibition. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic, or R/M, HNSCC excluding patients associated with human papillomavirus infection, or HPV-positive patients, with oropharyngeal squamous cell carcinoma, or OPSCC, late in the fourth quarter of 2024 or early in the first quarter of 2025. We are conducting an ongoing Phase 1/1b trial of ficerafusp alfa in the U.S., which includes a cohort of HNSCC patients who were treatment-naïve in the R/M setting. In this cohort, treatment with ficerafusp alfa in combination with pembrolizumab resulted in a 54% (21/39) overall response rate, or ORR, in the efficacy evaluable population, and a 64% (18/28) ORR in patients not associated with human papillomavirus infection, or HPV-negative patients. The historical response rate observed in a Phase 3 trial with pembrolizumab monotherapy, the current standard of care in R/M HNSCC, was 19%. Furthermore, treatment with ficerafusp alfa in combination with pembrolizumab demonstrated an 18% (5/28) complete response rate, or CR rate, and a median progression-free survival, or mPFS, of 9.8 months in HPV-negative patients. With at least 12 months of follow-up, median OS and median duration of response, or mDOR, have not yet been reached, and we expect to announce updated interim Phase 1/1b data at future medical meetings in 2025. Based on the clinical data generated to date, we believe that ficerafusp alfa in combination with pembrolizumab has the potential to become a first-line standard of care therapy in HPV-negative R/M HNSCC. We also believe ficerafusp alfa has the potential to provide meaningful clinical benefit in other solid tumors where there is a strong biologic rationale for the dual inhibition of both EGFR and TGF-ß, such as colorectal cancer and other squamous cell carcinomas which typically overexpress EGFR and TGF-ß pathways. We have demonstrated preliminary activity of ficerafusp alfa in combination with pembrolizumab or as a monotherapy across several squamous cell carcinomas, including cutaneous squamous cell carcinoma, or CSCC. Within our Phase 1/1b dose expansion cohorts conducted in the U.S. and Canada, we have observed to date a preliminary 42% (5/12) ORR with ficerafusp alfa monotherapy in relapsed and/or refractory CSCC patients. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the TME and limits systemic toxicity. This approach was deployed in the development of ficerafusp alfa, where we believe the bifunctional design can improve upon the therapeutic profile of immunotherapies and targeted therapies by addressing resistance mechanisms and limiting off-target toxicity, therefore, enhancing the treatment effect and tolerability for targeted patient populations with cancer. We were incorporated under the laws of the State of Delaware on December 12, 2018 under the name “Bicara Therapeutics Inc.” Our principal corporate office is located at 116 Huntington Avenue, Suite 703, Boston, MA 02116, and our telephone number is 617-468-4219. We have one subsidiary, Bicara Securities Corporation, formed in October 2023 under the laws of the Commonwealth of Massachusetts.
AI Analysis | Feedback
- Genentech for next-generation cancer antibody therapies.
- A specialized Regeneron Pharmaceuticals (REGN), focused on innovative cancer biologics.
AI Analysis | Feedback
- BCA101: A lead clinical-stage bifunctional antibody candidate designed to target both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β) pathways for the treatment of various solid tumors.
- Preclinical Pipeline: A portfolio of earlier-stage bifunctional immune checkpoint enhancer (BICE®) candidates aimed at undisclosed targets and indications, currently in research and preclinical development.
AI Analysis | Feedback
Bicara Therapeutics (BCAX) is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. As such, the company is currently engaged in research, development, and clinical trials for its drug candidates.
At its current stage of development, Bicara Therapeutics does not have commercial products on the market and therefore does not have major customers that it sells to in the traditional sense. Its operations are primarily funded through private and public investments (such as its recent initial public offering), rather than through sales of commercial products or services.
If Bicara Therapeutics successfully develops and gains regulatory approval for its drug candidates, its future "customers" would typically be pharmaceutical wholesalers, hospitals, or pharmacies, which would then distribute the medications to patients. Alternatively, the company might enter into licensing agreements with larger pharmaceutical companies, in which case those companies would become their partners/customers for the commercialization phase.
AI Analysis | Feedback
nullAI Analysis | Feedback
Claire Mazumdar, PhD, MBA Chief Executive Officer
Claire Mazumdar is the founding CEO of Bicara Therapeutics. She previously led business development and corporate strategy at Rheos Medicines, where she helped secure a significant partnership with Roche. As a Senior Associate at Third Rock Ventures, a venture capital firm, she focused on company formation and supported business development for its portfolio companies, indicating a pattern of involvement with privately backed firms.
Ivan Hyep, MBA Chief Financial Officer
Ivan Hyep previously served as Head of Finance at MOMA Therapeutics and as Director of Finance at Third Rock Ventures, LLC. Prior to that, he spent 10 years as a Financing Manager at Bain Capital, LP, a private investment firm, demonstrating a clear pattern of managing companies backed by private equity firms.
Ryan Cohlhepp, PharmD President & Chief Operating Officer
Ryan Cohlhepp serves as the President & Chief Operating Officer of Bicara Therapeutics.
David Raben, MD Chief Medical Officer
David Raben brings over 25 years of experience in biopharma and academic translational oncology. Before joining Bicara, he was Vice President of Global Product Development and Product General Manager, Oncology, at Amgen. Prior to Amgen, he served as Vice President and Franchise Leader, Clinical Development Oncology, at Genentech. He also spent more than 20 years as a professor and associate member at the University of Colorado Cancer Center.
Lara Meisner, JD Chief Legal Officer & Corporate Secretary
Lara Meisner previously held the position of Chief Legal Officer at Viridian Therapeutics, Inc., and served in various senior legal roles at Astria Therapeutics, Inc. and Verastem Oncology, Inc.
AI Analysis | Feedback
The key risks to Bicara Therapeutics (BCAX) primarily revolve around clinical development, financial sustainability, and market competition.
- Clinical Execution and Trial Data Risk: As a clinical-stage biopharmaceutical company, Bicara Therapeutics' success hinges on the successful progression and positive outcomes of its clinical trials. A significant risk is associated with the upcoming full dataset from the Phase 1/1b study and the ongoing pivotal Phase 2/3 FORTIFI-HN01 trial for its lead candidate, ficerafusp alfa, particularly in combination with KEYTRUDA for head and neck squamous cell carcinoma (HNSCC). Even with promising interim data and Breakthrough Therapy Designation, there is no assurance that final data will be positive or that it will translate into similar positive outcomes in later stages or broader patient populations. Negative or disappointing results, delays in trials, or a lack of translation from early-stage data to a viable commercial pathway could significantly impact the company.
- Financing Needs and Dilution Risk: Bicara Therapeutics is currently a company with no revenue and widening losses, having reported significant year-to-date losses. The company relies on its existing cash resources and the ability to raise additional capital to fund its research and development activities and operating expenses. While it has an at-the-market equity program in place, continued losses and the need for future funding introduce the risk of shareholder dilution through additional equity offerings. The ability to raise capital on reasonable terms is influenced by market confidence and clinical milestones.
- Competition Risk: Bicara Therapeutics operates in a highly competitive oncology market. Its lead candidate, ficerafusp alfa, faces direct competition from other companies developing therapies for similar indications, such as Merus's petosemtamab in the HNSCC field. Perceived superiority of rival clinical data, even if cross-trial comparisons are unreliable, can negatively impact Bicara's stock performance and future market positioning.
AI Analysis | Feedback
nullAI Analysis | Feedback
Bicara Therapeutics' (NASDAQ: BCAX) main product is ficerafusp alfa (BCA101), a first-in-class, dual-action, bifunctional antibody targeting EGFR and TGF-β.
The total addressable market for ficerafusp alfa in head and neck squamous cell carcinoma (HNSCC) is estimated to exceed $1.5 billion annually. This market size is presented in the context of the company's overall market potential, and while a specific region is not explicitly stated for the $1.5 billion figure, the global incidence of HNSCC is noted to approach one million new patients by 2030, with a significant incidence in the U.S.
AI Analysis | Feedback
Bicara Therapeutics (NASDAQ: BCAX), a clinical-stage biopharmaceutical company, anticipates its future revenue growth over the next 2-3 years to be primarily driven by the advancement and potential commercialization of its lead drug candidate, ficerafusp alfa. Here are 3-5 expected drivers of future revenue growth:- Commercialization of Ficerafusp Alfa in Head and Neck Squamous Cell Carcinoma (HNSCC): The most significant driver is the potential approval and launch of ficerafusp alfa for the treatment of first-line recurrent/metastatic HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). The company has reported promising Phase 1/1b trial results and has initiated a pivotal Phase 2/3 trial (FORTIFI-HN01) in this indication. Ficerafusp alfa has also been granted Breakthrough Therapy Designation by the U.S. FDA for 1L HPV-negative R/M HNSCC, which may facilitate an accelerated regulatory pathway.
- Expansion of Ficerafusp Alfa into Other Solid Tumor Indications: Beyond HNSCC, Bicara Therapeutics is evaluating ficerafusp alfa in other EGFR-driven advanced solid tumors. These include squamous cell carcinoma of the anal canal (SCAC) and cutaneous squamous cell carcinoma (CSCC), among others such as epithelial ovarian cancer, colorectal cancer, pancreas cancer, and squamous cell carcinoma of the lung. Successful clinical development and subsequent regulatory approvals in these additional indications would significantly broaden the market opportunity for ficerafusp alfa.
- Potential for Accelerated Regulatory Approval Pathways: The Breakthrough Therapy Designation granted to ficerafusp alfa for 1L HPV-negative R/M HNSCC could lead to increased interaction with the FDA, senior leadership involvement, and eligibility for rolling and priority review. This accelerated pathway has the potential to bring the drug to market sooner, thereby enabling earlier revenue generation.
AI Analysis | Feedback
Share Issuance
- Bicara Therapeutics completed its Initial Public Offering (IPO) on September 16, 2024, raising approximately $362 million in gross proceeds.
- The IPO involved the offering of 20,125,000 shares of common stock at a price of $18.00 per share, which included the full exercise of the underwriters' option for additional shares.
- As of October 2025, the number of outstanding shares for Bicara Therapeutics was 54,539,230.
Inbound Investments
- Bicara Therapeutics closed an oversubscribed $165 million Series C financing round on December 12, 2023.
- This Series C financing was co-led by Braidwell LP and TPG, with participation from other new and existing investors.
- The company has raised a total of $313 million across three funding rounds (Seed, Early-Stage, and Late-Stage), with the first round occurring on March 15, 2021.
Capital Expenditures
- In the last 12 months (as of August 12, 2025), Bicara Therapeutics reported capital expenditures of -$48,000.
- Annual capital expenditures were -$0.05 million in the most recent fiscal year (as of August 12, 2025), and were also reported as -$0.07 million, -$0.59 million, and -$0.19 million in prior years.
- As a clinical-stage biopharmaceutical company, Bicara Therapeutics relies on third-party manufacturing and service agreements to support its clinical trials and research and development, indicating a focus away from large internal manufacturing capital outlays.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 19.02 |
| Mkt Cap | 1.3 |
| Rev LTM | 192 |
| Op Inc LTM | -92 |
| FCF LTM | -90 |
| FCF 3Y Avg | 22 |
| CFO LTM | -89 |
| CFO 3Y Avg | 25 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.7% |
| Rev Chg 3Y Avg | 9.3% |
| Rev Chg Q | 3.7% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Mgn LTM | -52.5% |
| Op Mgn 3Y Avg | -67.6% |
| QoQ Delta Op Mgn LTM | 3.7% |
| CFO/Rev LTM | -47.8% |
| CFO/Rev 3Y Avg | -31.1% |
| FCF/Rev LTM | -49.2% |
| FCF/Rev 3Y Avg | -34.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.3 |
| P/S | 4.7 |
| P/EBIT | -1.9 |
| P/E | -1.9 |
| P/CFO | -1.8 |
| Total Yield | -9.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.4% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.2% |
| 3M Rtn | 25.9% |
| 6M Rtn | 45.1% |
| 12M Rtn | 18.8% |
| 3Y Rtn | -14.2% |
| 1M Excs Rtn | -5.6% |
| 3M Excs Rtn | 23.8% |
| 6M Excs Rtn | 36.2% |
| 12M Excs Rtn | 1.0% |
| 3Y Excs Rtn | -83.4% |
Price Behavior
Price Behavior
| Market Price | $15.36 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 09/13/2024 | |
| Distance from 52W High | -19.6% | |
| 50 Days | 200 Days | |
| DMA Price | $17.35 | $15.57 |
| DMA Trend | up | up |
| Distance from DMA | -11.5% | -1.3% |
| 3M | 1YR | |
| Volatility | 59.8% | 86.8% |
| Downside Capture | 32.13 | 202.21 |
| Upside Capture | 52.56 | 197.08 |
| Correlation (SPY) | 11.4% | 32.7% |
BCAX Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.23 | 0.23 | 0.41 | 0.77 | 1.45 | -0.02 |
| Up Beta | 7.75 | 5.00 | 2.43 | 0.86 | 1.22 | 0.69 |
| Down Beta | -0.22 | -0.48 | -0.06 | 0.02 | 1.08 | 1.26 |
| Up Capture | -113% | -44% | 17% | 175% | 366% | 52% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 16 | 27 | 62 | 124 | 171 |
| Down Capture | -170% | -19% | -2% | 51% | 144% | 104% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 25 | 34 | 61 | 122 | 168 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BCAX | |
|---|---|---|---|---|
| BCAX | 23.4% | 86.8% | 0.66 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 34.5% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 32.6% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | -3.9% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | 5.8% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 27.9% |
| Bitcoin (BTCUSD) | -27.1% | 44.7% | -0.57 | 24.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BCAX | |
|---|---|---|---|---|
| BCAX | -7.7% | 82.8% | 0.04 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 31.0% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 31.3% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 0.5% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 3.7% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 27.7% |
| Bitcoin (BTCUSD) | 16.1% | 58.0% | 0.49 | 19.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BCAX | |
|---|---|---|---|---|
| BCAX | -3.9% | 82.8% | 0.04 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 31.0% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 31.3% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | 0.5% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 3.7% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 27.7% |
| Bitcoin (BTCUSD) | 68.7% | 66.7% | 1.08 | 19.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | -4.8% | 1.0% | 30.5% |
| 8/12/2025 | 4.8% | 14.8% | 19.4% |
| 3/27/2025 | 2.3% | 1.2% | 11.0% |
| 11/12/2024 | -7.3% | -20.4% | -17.4% |
| SUMMARY STATS | |||
| # Positive | 2 | 3 | 3 |
| # Negative | 2 | 1 | 1 |
| Median Positive | 3.5% | 1.2% | 19.4% |
| Median Negative | -6.1% | -20.4% | -17.4% |
| Max Positive | 4.8% | 14.8% | 30.5% |
| Max Negative | -7.3% | -20.4% | -17.4% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hyep, Ivan | Chief Financial Officer | Direct | Sell | 12232025 | 18.31 | 9,200 | 168,492 | 2,662,075 | Form |
| 2 | Cohlhepp, Ryan | President and COO | Direct | Sell | 12162025 | 18.68 | 12,500 | 233,548 | 3,533,873 | Form |
| 3 | Hyep, Ivan | Chief Financial Officer | Direct | Sell | 11252025 | 18.15 | 605 | 10,981 | 2,638,193 | Form |
| 4 | Hyep, Ivan | Chief Financial Officer | Direct | Sell | 11252025 | 18.55 | 17,795 | 330,094 | 2,696,306 | Form |
| 5 | Cohlhepp, Ryan | President and COO | Direct | Sell | 11252025 | 18.05 | 12,500 | 225,588 | 3,494,639 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.